Evaluating the impact of All4Cure on patient activation in multiple myeloma
Impact of a Health Technology Intervention on Patient Activation in Multiple Myeloma
This study is testing if joining the All4Cure platform helps people with multiple myeloma feel more engaged and informed about their health over a year.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 200 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | All4Cure Industry-sponsored |
| Locations | 7 sites (Fayetteville, Arkansas and 6 other locations) |
| Trial ID | NCT05673083 on ClinicalTrials.gov |
What this trial studies
This pilot study aims to assess how enrollment in the All4Cure platform affects patient activation among individuals diagnosed with multiple myeloma. Participants will complete the PAM-13 survey quarterly and monthly Patient Reported Outcome surveys through the All4Cure website over a 12-month period. The study will evaluate changes in patient activation and perceptions of the All4Cure platform from baseline to the end of the study. Additionally, physicians caring for enrolled patients will provide feedback on their experiences with the study.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older with a diagnosis of multiple myeloma who can complete surveys and have access to the necessary technology.
Not a fit: Patients who are unable to engage with the All4Cure platform or are already participants in All4Cure may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance patient engagement and empowerment in managing multiple myeloma.
How similar studies have performed: While this approach is relatively novel, similar studies focusing on patient activation and engagement have shown promising results.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. have a diagnosis of multiple myeloma. 2. are aged 18 years and older. 3. can read and e-consent to participate in the study. 4. can speak English. 5. can complete surveys at pre-specified intervals. 6. have access to a device that would allow for the completion of surveys (including at home, at work, at the oncologist's office or elsewhere). 7. are cared for by a physician who is enrolled in All4Cure. Exclusion Criteria: 1. Patients will be excluded who are unable to engage with All4Cure or are already participants in All4Cure.
Where this trial is running
Fayetteville, Arkansas and 6 other locations
- Highlands Oncology Group — Fayetteville, Arkansas, United States (Active_not_recruiting)
- Cancer Specialists of North Florida — Jacksonville, Florida, United States (Active_not_recruiting)
- Misson Cancer + Blood — Des Moines, Iowa, United States (Active_not_recruiting)
- Hematology-Oncology Associates of Central New York — East Syracuse, New York, United States (Active_not_recruiting)
- Oklahoma Cancer Specialists and Research Institute — Tulsa, Oklahoma, United States (Recruiting)
- Oncology Consultants — Houston, Texas, United States (Active_not_recruiting)
- Northwest Medical Specialties PLLC — Tacoma, Washington, United States (Active_not_recruiting)
Study contacts
- Study coordinator: Carl A Blau, MD
- Email: tony@all4cure.com
- Phone: 206-412-1787
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.